Edmonton, Alberta — October 16, 2025 — Leads & Copy — Innovotech Inc. (TSX-V: IOT) is advancing its expansion into analytical laboratory services through strategic initiatives, including an offering to raise up to $200,000 via an unsecured convertible debenture. The debenture will have an 8% interest rate paid quarterly and mature in 60 months, with the principal convertible into common shares at $0.25 per share.
The funds will support expansion within Innovotech’s Keystone Labs division, enabling hazardous drug testing and enhancing analytical capabilities through advanced equipment. The company is also welcoming Jeff Kelly to the team to help establish Innovotech as a trusted provider of analytical services.
Innovotech anticipates a related party will be the single participant in the offering. The related party has also given notice that it intends to exercise 384,615 Innovotech share purchase warrants at $0.17 acquired pursuant to the terms of a private placement that closed on November 6, 2024 for consideration of $65,384.55.
According to CEO Craig Milne, these investments mark a pivotal step for Innovotech, strengthening its role as a contract research organization serving industries reliant on rigorous scientific validation. He added that the company sees strong potential to extend its deep integration in its clients’ product development activities into adjacent analytical markets.
Contact: Craig Milne, CEO Innovotech Inc. +1-604-239-1819 craig.milne@innovotech.ca
Source: Innovotech Inc.
